CellCentric
Industry
Oncology / Haematology
Website
HBM contact
Company status
Private
Clinical-stage biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor for the treatment of relapsed/refractory multiple myeloma and other cancers.
